Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma

This case report shows, for the first time, a patient experiencing a complete response after one dose of avelumab following extensive disease progression with prior electrochemotherapy (ECT) treatment. We suggest that ECT may help to establish a tumor microenvironment favorable to immunotherapy. Merkel cell carcinoma (MCC) is a highly aggressive skin cancer with seldom durable chemotherapy responses. ECT has recently emerged as a potential treatment option for several malignancies, including MCC. Avelumab, an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody, became the first approved treatment for patients with metastatic MCC. ECT has been shown to activate the immune response, but it is still unknown how ECT may affect patient’s response to subsequent immunotherapy. We report a case of a patient with MCC who presented with a rapidly growing skin nodule of the right cheek and experienced extensive disease progression following surgical debulking and ECT treatment. The patient received a flat dose of 800 mg avelumab intravenously every 2 weeks showing complete tumor regression after only one dose. Immunohistochemical analysis of surgical and post-ECT biopsies collected from the primary lesion revealed tumor expression of programmed cell death protein-1 (PD-1), but not PD-L1. Analysis of the tumor samples also revealed no expression of Merkel cell polyomavirus (MCPyV). Comparison of the biopsies showed a decrease in myeloid and T-cell markers after ECT but an increase in major histocompatibility complex (MHC) class I expression on tumor cells. Additionally, the patient experienced an increase in neutrophil-to-lymphocyte ratio and lactate dehydrogenase values post-ECT, which subsequently decreased with avelumab treatment. As of 30 October 2019, the patient was still receiving avelumab treatment and had an ongoing complete response. In this case report, a patient with PD-L1-negative and MCPyV-negative MCC who had disease progression following ECT experienced complete tumor regression with avelumab treatment, suggesting, for the first time to our knowledge, that ECT may help to establish a tumor microenvironment favorable to immunotherapy via a potential abscopal effect. Tumor-intrinsic PD-1 expression and modulation of MHC class I antigens after ECT may contribute to the clinical efficacy of avelumab in this context.

[1]  Parantu K. Shah,et al.  Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial , 2020, Journal for immunotherapy of cancer.

[2]  T. Steiniche,et al.  Tumor Ulceration, Reduced Infiltration of CD8-Lymphocytes, High Neutrophil-to-CD8-Lymphocyte Ratio and Absence of MC Virus are Negative Prognostic Markers for Patients with Merkel Cell Carcinoma , 2020, Cancers.

[3]  G. Gao,et al.  Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy , 2020, Proceedings of the National Academy of Sciences.

[4]  C. Drake,et al.  34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1 , 2019, Journal of Immunotherapy for Cancer.

[5]  M. Tetzlaff,et al.  Danger is only skin deep: aggressive epidermal carcinomas. An overview of the diagnosis, demographics, molecular-genetics, staging, prognostic biomarkers, and therapeutic advances in Merkel cell carcinoma , 2019, Modern Pathology.

[6]  A. Sykes,et al.  Electrochemotherapy and Ablative Therapies in Non-melanoma Skin Cancer. , 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

[7]  Howard Y. Chang,et al.  Clonal replacement of tumor-specific T cells following PD-1 blockade , 2019, Nature Medicine.

[8]  V. Mazzaferro,et al.  Microenvironment and tumor inflammatory features improve prognostic prediction in gastro‐entero‐pancreatic neuroendocrine neoplasms , 2019, The journal of pathology. Clinical research.

[9]  G. Linette,et al.  A Single Dose of Neoadjuvant PD-1 Blockade Predicts Clinical Outcomes in Resectable Melanoma , 2019, Nature Medicine.

[10]  J. Taube,et al.  Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Carola Berking,et al.  Melanoma , 2018, The Lancet.

[12]  J. Grob,et al.  Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial , 2018, JAMA oncology.

[13]  A. Stang,et al.  Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics , 2017, Journal of the American Academy of Dermatology.

[14]  J. Becker,et al.  Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC , 2018, Cancer Immunology, Immunotherapy.

[15]  C. Garbe,et al.  Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy , 2017, Reviews in Endocrine and Metabolic Disorders.

[16]  Lu Shi,et al.  Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. , 2017, Cancer Treatment Reviews.

[17]  J. Schlom,et al.  Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. , 2017, The Lancet. Oncology.

[18]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[19]  D. Schadendorf,et al.  Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. , 2017, European journal of cancer.

[20]  G. Linette,et al.  Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. , 2016, The Lancet. Oncology.

[21]  N. Pimpinelli,et al.  CD4+FOXP3+ T regulatory cells decrease and CD3+CD8+ T cells recruitment in TILs from melanoma metastases after electrochemotherapy , 2016, Clinical & Experimental Metastasis.

[22]  A. Sober,et al.  Analysis of Prognostic Factors from 9387 Merkel Cell Carcinoma Cases Forms the Basis for the New 8th Edition AJCC Staging System , 2016, Annals of Surgical Oncology.

[23]  George F. Murphy,et al.  Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth , 2015, Cell.

[24]  D. Miklavčič,et al.  Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer , 2015, Cancer Immunology, Immunotherapy.

[25]  M. Benazzo,et al.  Electrochemotherapy as a new therapeutic strategy in advanced Merkel cell carcinoma of head and neck region , 2013, Radiology and oncology.

[26]  S. Calvieri,et al.  Remission of extensive merkel cell carcinoma after electrochemotherapy. , 2009, Archives of dermatology.

[27]  M. Ming,et al.  Merkel cell carcinoma , 2004, Current treatment options in oncology.